-
公开(公告)号:US12115198B2
公开(公告)日:2024-10-15
申请号:US16590569
申请日:2019-10-02
IPC分类号: A61K35/742 , A23K10/18 , A23K20/189 , A23K20/195 , A23K50/10 , A23K50/30 , A61K9/00 , A61K35/741 , A61K45/06 , A61P3/00 , A61K35/00
CPC分类号: A61K35/742 , A23K10/18 , A23K20/189 , A23K20/195 , A23K50/10 , A23K50/30 , A61K9/0056 , A61K9/0095 , A61K35/741 , A61K45/06 , A61P3/00 , A61K2035/115
摘要: The invention relates to direct-fed microbials for use in improving reproductive performance in animals, decreasing death loss and/or off-feed events in animals, improving milk production and/or milk quality in dairy animals, and inhibiting a disease or disorder in dairy animals selected from the group consisting of milk fever, ketosis, retained placenta, metritis, pneumonia, and displaced abomasum. More particularly, the invention relates to isolated Bacillus strains 86, 300, 101, 235, 177, and 102, and strains having all of the identifying characteristics of these strains, for uses comprising the above-mentioned uses.
-
公开(公告)号:US12109244B2
公开(公告)日:2024-10-08
申请号:US18109785
申请日:2023-02-14
发明人: Larry D. Sutton
IPC分类号: A61K36/064 , A61K9/28 , A61K9/48 , A61K9/50 , A61K31/327 , A61K35/74 , A61K35/742 , A61K35/748 , A61K38/44 , A61P31/04
CPC分类号: A61K36/064 , A61K9/28 , A61K9/4825 , A61K9/5042 , A61K31/327 , A61K35/742 , A61K35/748 , A61K38/44 , A61P31/04
摘要: Agents, kits, and methods that utilize oxygenation to prevent and/or treat intestinal inflammation and/or infections caused by anaerobic microorganisms are provided. In several embodiments, the formulations are provided as a capsule within a capsule in order to separate an oxygen prodrug from a catalyst until the formulation is at a target site within the intestine. In several embodiments, the catalyst is provided in an excess of the oxygen prodrug. In several embodiments, the prodrug is within an inner capsule or coating and a biological material comprising a catalyst (e.g., yeast, spirulina, chlorella, etc.) surrounds the encapsulated prodrug and the biological material is within a capsule or coating. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy.
-
公开(公告)号:US20240316123A1
公开(公告)日:2024-09-26
申请号:US18616811
申请日:2024-03-26
申请人: ZBiotics Company
发明人: Zachary Abbott
IPC分类号: A61K35/742 , A61K9/00 , A61K35/00 , A61K35/741 , A61K38/00 , A61P39/02 , C07K14/32 , C12N9/02 , C12N15/63
CPC分类号: A61K35/742 , A61K9/0053 , A61P39/02 , C07K14/32 , C12N9/0008 , C12N15/63 , C12Y102/01003 , A61K9/0095 , A61K2035/115 , A61K35/741 , A61K38/00
摘要: Provided herein are recombinant microorganisms that express a subject polypeptide. Microorganisms can comprise an expression construct comprising a flagellin promoter operatively linked with a heterologous nucleotide sequence encoding the subject polypeptide. The flagellin promoter sequence can comprise a genetic modification that reduces CsrA inhibition of translation. Microorganisms also can comprise a genetic modification that reduces FlgM inhibition of SigD initiation of transcription. The target polypeptide can be an aldehyde dehydrogenase. Such microorganisms are useful in the treatment of alcohol hangover.
-
公开(公告)号:US20240277789A1
公开(公告)日:2024-08-22
申请号:US18633805
申请日:2024-04-12
发明人: Jessica MALOH , Barbara A. PALDUS , Raja SIVAMANI
IPC分类号: A61K35/747 , A61K9/00 , A61K31/353 , A61K31/57 , A61K35/00 , A61K35/742 , A61K35/745 , A61K36/328 , A61K36/82 , A61K45/06 , A61P17/10
CPC分类号: A61K35/747 , A61K9/0053 , A61K31/353 , A61K31/57 , A61K35/742 , A61K35/745 , A61K36/328 , A61K36/82 , A61K45/06 , A61P17/10 , A61K2035/115
摘要: The present disclosure relates to compositions and methods useful for dietary augmentation to provide therapeutic intervention for the treatment and management of acne-prone skin. According to one embodiment of the present disclosure, there is provided an orally administrable composition containing a therapeutically effective amount of: (a) a probiotic blend of bacterial components containing at least: (i) Lactobacillus acidophilus, (ii) Bifidobacterium lactis, an (iii) Bacillus coagulans; (b) guggul; and (c) green tea leaf.
-
5.
公开(公告)号:US20240261342A1
公开(公告)日:2024-08-08
申请号:US18566194
申请日:2022-05-31
IPC分类号: A61K35/742 , A61P31/16 , A61P37/04 , C12N1/20 , C12R1/145
CPC分类号: A61K35/742 , A61P31/16 , A61P37/04 , C12N1/205 , C12R2001/145
摘要: This invention relates to bacterial strains of the genus Blautia, compositions comprising bacterial said bacterial strains as well as methods and uses of said strains and compositions as a medicament, in particular for preventing, treating and/or reducing symptoms associated with a rhinovirus-induced common cold infection in a subject in need thereof.
-
公开(公告)号:US12053447B2
公开(公告)日:2024-08-06
申请号:US16452151
申请日:2019-06-25
申请人: NuBioPharma, LLC
IPC分类号: A61K31/197 , A61K9/00 , A61K35/741 , A61K35/742 , A61K35/745 , A61K35/747 , A61K47/02 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26
CPC分类号: A61K31/197 , A61K9/0053 , A61K9/009 , A61K35/741 , A61K35/742 , A61K35/745 , A61K35/747 , A61K47/02 , A61K47/12 , A61K47/186 , A61K47/22 , A61K47/26
摘要: A pharmaceutical composition for preparation of an orally administered liquid solution containing a therapeutically sufficient dose of dissolved balsalazide. The composition further comprises three artificial sweeteners comprising sucralose, acesulfame potassium and ammonium glycyrrhizinate that unexpectedly mitigate the bitter attributes of the orally administered liquid balsalazide solution that would otherwise render the solution unpalatable. More particularly, the present disclosure relates to a composition of the three artificial sweeteners and a therapeutically sufficient dose of balsalazide for the treatment of bowel disorders such as ulcerative colitis. Unit dose sachets of balsalazide disodium 750 mg and 2,250 mg of powder to oral solution are also disclosed. The disclosure further provides a kit including a dissolvable solid phase composition of the three artificial sweeteners and dissolvable solid phase therapeutically sufficient dose of balsalazide and further comprising a therapeutic dose of a probiotic (bacillus) to enhance the azoreduction of the balsalazide in the colon.
-
公开(公告)号:US20240148803A1
公开(公告)日:2024-05-09
申请号:US18546922
申请日:2022-02-18
发明人: Christopher B. FORD , Elizabethh HALVORSEN , Christopher DESJARDINS , Kankana BARDHAN , Swarma Deepa PANDIAN
IPC分类号: A61K35/742 , A61K35/745 , A61K45/06 , A61P35/04
CPC分类号: A61K35/742 , A61K35/745 , A61K45/06 , A61P35/04
摘要: Provided herein are methods and compositions for the treatment of various types of cancers by modulating the microbiome to effect or enhance the efficacy of immunotherapy. Also provided herein are methods of determining a response to an immunotherapy by identifying if a subject has a favorable microbial profile. Further provided herein are methods of determining a donor whose feces are useful for fecal matter transfer.
-
公开(公告)号:US20240148802A1
公开(公告)日:2024-05-09
申请号:US18504131
申请日:2023-11-07
IPC分类号: A61K35/742 , A23K10/18 , A23K20/111 , A23K20/121 , A23K20/158 , A23K50/30 , A61K9/00 , A61K31/192 , A61K31/20 , A61K31/593 , A61K47/18 , A61K47/46 , A61P31/04
CPC分类号: A61K35/742 , A23K10/18 , A23K20/111 , A23K20/121 , A23K20/158 , A23K50/30 , A61K9/0056 , A61K31/192 , A61K31/20 , A61K31/593 , A61K47/183 , A61K47/186 , A61K47/46 , A61P31/04 , A61K2035/115
摘要: The present disclosure describes products formulated to mitigate viral and bacterial infections in swine, along with associated methods of providing such products to the animals. Feeding methods involve providing animals with a feed product that includes a medium chain fatty acid composition, a direct-fed microbial composition, along with one or more flavonoids and/or organic acids. The medium chain fatty acid composition includes one or more of caproic acid, caprylic acid, capric acid and lauric acid. The direct-fed microbial composition includes one or more strains of Bacillus. The animals can include swine at risk of developing, or already afflicted with, a respiratory condition such as porcine reproductive respiratory syndrome or pneumonia.
-
9.
公开(公告)号:US20240139261A1
公开(公告)日:2024-05-02
申请号:US18051017
申请日:2022-10-31
申请人: TCI CO., LTD.
发明人: YUNG-HSIANG LIN , CHU-HAN HUANG , YI-LIN CHEN
IPC分类号: A61K35/747 , A61K35/742 , A61K35/745 , A61P1/14
CPC分类号: A61K35/747 , A61K35/742 , A61K35/745 , A61P1/14
摘要: Provided is a composition for improving gut microbiota, including: a bacterial species combination consisting of Limosilactobacillus fermentum TCI275 with an accession number of BCRC 910940, Bifidobacterium animalis subsp. lactis TCI604 with an accession number of BCRC 910887, and Weizmannia coagulans TCI803 with an accession number of BCRC 910946. Provided is a method for improving gut microbiota of a subject in need thereof with the bacterial species combination.
-
公开(公告)号:US20240122210A1
公开(公告)日:2024-04-18
申请号:US18394679
申请日:2023-12-22
发明人: Mallory EMBREE , Luke PICKING , Grant GOGUL , Janna TARASOVA
IPC分类号: A23K10/18 , A23K10/30 , A23K10/37 , A23K20/158 , A23K20/163 , A23K20/28 , A23K40/35 , A23K50/10 , A23L31/10 , A23L33/135 , A61K9/00 , A61K35/74 , A61K35/741 , A61K35/742 , A61K36/06 , A61K36/062 , A61K36/064 , A61K39/02 , A61P15/04 , A61P31/04 , C12N1/14 , C12N1/20
CPC分类号: A23K10/18 , A23K10/30 , A23K10/37 , A23K20/158 , A23K20/163 , A23K20/28 , A23K40/35 , A23K50/10 , A23L31/10 , A23L33/135 , A61K9/0019 , A61K9/0053 , A61K35/74 , A61K35/741 , A61K35/742 , A61K36/06 , A61K36/062 , A61K36/064 , A61K39/02 , A61P15/04 , A61P31/04 , C12N1/14 , C12N1/20 , A61K35/748
摘要: The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome.
-
-
-
-
-
-
-
-
-